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Background: Experimental autoimmune encephalomyelitis (EAE) is a model of inflammatory demyelinating
diseases mediated by different types of leukocytes. How these cells communicate with each other to orchestrate
autoimmune attacks is not fully understood, especially in the case of neutrophils, whose importance in EAE is newly
established. The present study aimed to determine the expression pattern and role of different components of the
IL-36 signaling pathway (IL-36α, IL-36β, IL-36γ, IL-36R) in EAE.
Methods: EAE was induced by either active immunization with myelin peptide, passive transfer of myelin-reactive
T cells or injection of pertussis toxin to transgenic 2D2 mice. The molecules of interest were analyzed using a
combination of techniques, including quantitative real-time PCR (qRT-PCR), flow cytometry, Western blotting, in
situ hybridization, and immunohistochemistry. Microglial cultures were treated with recombinant IL-36γ and
analyzed using DNA microarrays. Different mouse strains were subjected to clinical evaluation and flow cytometric
analysis in order to compare their susceptibility to EAE.
Results: Our observations indicate that both IL-36γ and IL-36R are strongly upregulated in nervous and
hematopoietic tissues in different forms of EAE. IL-36γ is specifically expressed by neutrophils, while IL-36R is
expressed by different immune cells, including microglia and other myeloid cells. In culture, microglia respond to
recombinant IL-36γ by expressing molecules involved in neutrophil recruitment, such as Csf3, IL-1β, and Cxcl2.
However, mice deficient in either IL-36γ or IL-36R develop similar clinical and histopathological signs of EAE
compared to wild-type controls.
Conclusion: This study identifies IL-36γ as a neutrophil-related cytokine that can potentially activate microglia, but
that is only correlative and not contributory in EAE.
Keywords: IL-36 gamma, IL-1 F9, IL-1Rl2, IL-1Rrp2, Granulocytes, Microglial cells, Neuroinflammation,
Autoimmunity, Multiple sclerosisBackground
Experimental autoimmune encephalomyelitis (EAE) is
an inflammatory demyelinating disease of the central
nervous system (CNS) that can be induced in animals to
model immunological processes involved in human dis-
eases such as multiple sclerosis, neuromyelitis optica,
and acute disseminated encephalomyelitis. EAE is initi-
ated by CD4+ T helper lymphocytes of the Th1 or Th17* Correspondence: Luc.Vallieres@crchul.ulaval.ca
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receptors [1]. These cells do not act alone, but in concert
with different myeloid cells, including monocyte-derived
CD11c+ dendritic cells [2–5], which activate them by pre-
senting the myelin peptides together with costimulatory
signals [6–12], and monocyte-derived macrophages [2, 4,
13, 14], which execute effector functions leading to de-
myelination [15]. In addition, recent studies have estab-
lished that neutrophils importantly contribute to EAE
[16–19], although their precise role is still unclear.
To coordinate their actions, immune cells must com-
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Many of these molecules have been studied in the con-
text of EAE in the hope of identifying potential thera-
peutic targets. For example: GM-CSF derives from T
cells and promotes dendritic cell recruitment [20, 21],
IL-12 and IL-23 are secreted by dendritic cells to sustain
T cell activation [22], and IL-1β is released from differ-
ent myeloid cells to induce inflammatory responses [23].
However, no neutrophil-specific cytokine has been iden-
tified to date.
Following a study conducted to clarify the mechanism
underlying the adjuvant effect of pertussis toxin (PTX)
in EAE [24], we compared the transcriptional profiles of
peritoneal leukocytes isolated from mice injected or not
with PTX using DNA microarrays (unpublished data).
Among the most upregulated genes was IL-36γ (also
called IL1F9), a newly characterized cytokine of the IL-1
family [25]. The IL-36–IL-36R signaling pathway com-
prises three agonists (IL-36α, IL-36β, IL-36γ), two antag-
onists (IL-36RA, IL-38), one specific receptor subunit
(IL-36R), and one accessory receptor subunit (IL-1RAcP)
that is shared with the classical interleukin-1 receptor
(IL-1R). The IL-36 proteins exhibit a typical β-trefoil
structure [26] whose activity is enhanced by N-terminal
truncation [27].
In the CNS, the expression of IL-36γ has never been
studied, but that of IL-36R has been reported under nor-
mal conditions in non-neuronal elements such as the
meninges, choroid plexus, and perivascular cells [28]. In
the periphery, IL-36γ expression is constitutive in epi-
thelial cell lines and inducible in myeloid cells (mono-
cytes, macrophages, dendritic cells) by inflammatory
mediators (e.g., IL-1β, TNF, IL-17, IL-23, TLR ligands)
[29–37]. IL-36R is found on keratinocytes, splenic CD4+
T cells, and different myeloid cells [38–40].
IL-36γ promotes not only inflammation but also den-
dritic cell maturation and ability to generate a Th1 re-
sponse. Indeed, recombinant IL-36γ induces cytokines
and chemokines (e.g., IL-6, IL-8, Csf2, Csf3, Cxcl1,
Ccl20) when injected into epithelial tissues, resulting in
neutrophil and T cell infiltration [31, 40–42]. Further-
more, IL-36γ stimulates dendritic cells to produce
inflammatory mediators (e.g., IL-6, IL-1β, IL-12p40, IL-
12p35, IL-23p19, Cox-2, Cxcl1, Csf2) and cell surface
receptors involved in antigen presentation (e.g., MHCII,
CD80, CD83, CD86) [38–40]. IL-36γ can also induce
CD4+ T cells to adopt an inflammatory IFNγ+ Th1 pro-
file even in the absence of antigen-presenting cells, indi-
cating that it can directly signal through IL-36R on T
cells [38]. Consistently, the IL-36–IL-36R axis was
found to be involved in psoriasis [29, 32, 34, 43–50], but
the possibility that it also contributes to other T cell-
driven autoimmune diseases such as multiple sclerosis
remains to be determined.The goal of the present study was to test the hypoth-
esis that myeloid cells produces IL-36γ during EAE to
promote inflammatory Th1/Th17 responses towards
myelin. The findings presented below demonstrate that
IL-36γ is specifically and strongly expressed by neutro-
phils in both CNS and hematopoietic compartments
during certain forms of EAE and that microglia can
react to IL-36γ by releasing neutrophil-related cytokines;
however, IL-36γ does not influence the clinical and
histopathological signs of EAE.Methods
Animals
C57BL/6 mice were obtained from The Jackson Labora-
tory. Colonies of IL-36γ–/–, IL-36R–/–, and 2D2 mice
(C57BL/6 background) were generated from breeders
provided by the Mutant Mouse Regional Resource Cen-
ter, Amgen or The Jackson Laboratory, respectively. The
genotypes were confirmed by PCR using the primers
listed in Additional file 1: Table S1. The experiments
were performed on male mice aged 8–10 weeks under
specific pathogen-free conditions with the approval of
the Laval University Animal Protection Committee.EAE induction by active immunization
Mice were subcutaneously injected into both flanks
with a total of 200 μl of emulsion containing 300 μg
of MOG35-55 peptide (Feldan) dissolved in saline and
mixed with an equal volume of complete Freund’s
adjuvant containing 500 μg of killed Mycobacterium
tuberculosis H37 RA (Difco Laboratories). They were
also injected intraperitoneally with 20 μg/kg of PTX
(List Biological Laboratories) immediately and 2 days
after immunization.EAE induction by adoptive transfer
Mice were intraperitoneally injected with 20 × 106 en-
cephalitogenic cells. These were isolated from abdominal
lymph nodes and spleens of mice killed 8 days after ac-
tive EAE induction and then cultured for 2 days in
DMEM with MOG35-55 peptide (15 μg/ml), murine IL-
12 (5 ng/ml, R&D Systems), murine IL-23 (20 ng/ml,
R&D Systems), heat-inactivated HyClone bovine growth
serum (10 %, Thermo Scientific), modified Eagle’s
medium non-essential amino acids (1 %, Wisent), peni-
cillin (100 U/ml), streptomycin (100 μg/ml), and ampho-
tericin B (250 ng/ml).EAE induction in 2D2 mice
2D2 mice received two intraperitoneal injections of PTX
(20 μg/kg) at a 2-day interval.
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Mice were weighed and scored daily as follows: 0, no vis-
ual sign of disease; 0.5, partial tail paralysis; 1, complete
tail paralysis; 1.5, weakness in one hindlimb; 2, weakness
in both hindlimbs; 2.5, partial hindlimb paralysis; 3,
complete hindlimb paralysis; 3.5, partial forelimb paralysis;
4, complete forelimb paralysis; and 5, dead or killed for
humane reasons.
Cell suspension and flow cytometry
Mice were anesthetized and exsanguinated by cardiac
perfusion with saline. Spinal cords were harvested,
minced with razor blades in Dulbecco’s phosphate-
buffered saline (DPBS, with Ca2+ and Mg2+), digested for
45 min at 37 °C in DPBS containing 0.13 U/ml Liberase
TM (Roche Diagnostics) and 50 U/ml DNase I (Sigma-
Aldrich), filtered through 40-μm cell strainers, and then
separated from myelin debris by centrifugation in 35 %
Percoll (GE Healthcare). The spleens were mashed
through 40-μm cell strainers and treated with ammonium
chloride solution (Stemcell Technologies) to remove re-
sidual erythrocytes. For immunostaining, the cells were in-
cubated sequentially with rat anti-CD16/CD32 antibody
(5 μg/ml, BD Biosciences, clone 2.4G2) and Fixable viability
dye eFluor 506 (1:1000, eBioscience) for 5 min, with anti-
IL-36R antibody (Abcam #ab171844 or R&D Systems
#AF2354) for 30 min, and with combinations of the
following antibodies for 30 min: rat anti-CD45-FITC
(BD Biosciences, clone 30-F11), rat anti-CD11b-V450
(BD Biosciences, clone M1/70), rat anti-Ly6G-APC-
Cy7 (Biolegend, clone 1A8), rat anti-CD3ε-PE (BD Biosci-
ences, clone 145-2C11), rat anti-CD19-PerCP-Cy5.5, (BD
Biosciences, clone 1D3), rat anti-CD11c-Alexa 647 (Biole-
gend, clone N418), and goat anti-rabbit IgG-Alexa 594
(Invitrogen, Cat No A11072). The latter antibodies were di-
luted at 1:200, except anti-CD45-FITC, which was diluted
at 1:100. Isotype control antibodies and fluorescence-
minus-one controls were used for gating. Cells were
washed and resuspended in PBS before being analyzed
with a FACSAria II flow cytometer (BD Biosciences).
All the analyses were performed by excluding dead
cells and doublets using FlowJo software (Tree Star,
version 10.0.7r2).
Western blotting
Ly6G+ neutrophils, isolated by flow cytometry, were
homogenized in extraction buffer (50 mM Tris-HCl
at pH 7.4, 150 mM NaCl, 1 % Triton X-100, 1 mM
ethylenediaminetetraacetic acid, 1 mM ethylene glycol
tetraacetic acid, 2 mM Na pyrophosphate, 10 mM Na
β-glycerophosphate, 1 mM Na orthovanadate, 1 mM
phenylmethanesulfonylfluoride, 1× protease and phos-
phatase inhibitor cocktail [Sigma]). The protein samples
(50 μg) were resolved in a 12 % SDS-PAGE Mini-ProteanPrecast gel (Bio-Rad) and transferred to a polyvinylidene
difluoride membrane (PerkinElmer). The membrane was
blocked in PBS containing 0.1 % Tween 20 and 7 % non-fat
milk, and then incubated at 4 °C overnight with an anti-
body against IL-36γ (1:200, Santa Cruz, sc-168163) or
β-actin (1:50000, Abcam, mab150), followed by 1 h at
room temperature in the appropriate secondary horse-
radish peroxidase-conjugated antibody (Cell Signaling
Technology). The antibodies were detected using the
Western Lightning Plus-ECL chemiluminescence sub-
strate (Perkin Elmer).
Immunostaining
Immunostaining was performed as described previously
[51] using the following primary antibodies: rat anti-CD3
(1:500, BD Biosciences, clone 17A2) and rat anti-Ly6G
(1:5000, BD Biosciences, clone 1A8).
In situ hybridization
Spinal cord sections were analyzed for IL-36γ and IL-36R
mRNAs by radioisotopic in situ hybridization as described
previously [52].
Microscopy
Micrographs were taken using a Retiga EX camera on a
Nikon E800 microscope. Images were adjusted for contrast,
brightness, and sharpness using Photoshop 12 (Adobe
Systems).
Microglial cell isolation and culture
Primary microglia were isolated from newborn mice
(1 day old or less). The brains were minced with razor
blades in DPBS and passed four times through a 20-G
needle. After centrifugation (1500 rpm), the pellets were
resuspended and incubated at 37 °C for 15 min in DPBS
containing 0.25 % trypsin-EDTA (Wisent) and 50 U/ml
DNase I. The cells were plated in T-25 flasks (~3 brains/
flask) and grown in Dulbecco’s modified Eagle’s medium
(Wisent) supplemented with 10 % heat-inactivated
HyClone bovine growth serum, with medium changed
every 2 days. After 2 weeks, the microglia were separated
from other glial cells as described previously [53]. Briefly,
they were incubated with 0.05 % trypsin in DMEM at
37 °C for 30–45 min, rinsed with PBS to remove con-
taminating non-adherent cells, then grown in a 1:1 mix-
ture of fresh media and conditioned media from mixed
glial cultures (2–3 days). Microglial purity was >99 %, as
determined by flow cytometry using the myeloid cell
marker CD11b.
For experimentation, primary microglia were seeded
in 12-well plates and used at ~70 % confluence (after
5–7 days). BV2 microglia were seeded in 12-well plates
at a density of 500,000 cells and used on the next day.
Cells were stimulated with 100 ng/ml recombinant
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PBS as control. After 6 h, the cells were rinsed with
PBS, resuspended in lysis buffer and stored at −80 °C
until RNA extraction.
RNA extraction and qRT-PCR
Total RNA from tissues and cells was isolated by
homogenization in TRI-reagent or lysis buffer (Sigma-
Aldrich), respectively. GenElute Mammalian Total RNA
Miniprep Kit (Sigma-Aldrich) was used for RNA purifi-
cation. First strand cDNA was generated from 5 (tissues)
or 1 (cells) μg of total RNA using Superscript III (Invitro-
gen) with random hexamers and 20-mer oligo-dT primers,
then purified using the GenElute PCR Clean-Up Kit
(Sigma-Aldrich). The product (20 ng) was analyzed using
the LightCycler 480 system with the SYBR Green I Master
mix and primers listed in Additional file 2: Table S2 accord-
ing to the manufacturer’s instructions (Applied Biosystems).
The PCR conditions consisted of 45 cycles of denatur-
ation (10 s at 95 °C), annealing (10 s at 60 °C), elong-
ation (14 s at 72 °C), and reading (5 s at 74 °C). The
number of mRNA copies was determined using the
second derivative method [54].
Statistical analyses
Data are expressed as mean ± standard error. Means
were compared using the Wilcoxon or Kruskal-Wallis
test, except for the microarray data, which were com-
pared using Student’s t test. EAE incidence curves were
constructed using the Kaplan-Meier method and com-
pared using the Wilcoxon test. All these analyses were
performed using JMP 10 (SAS Institute) with a signifi-
cance level of 5 %.
Results
Neutrophils express IL-36γ in the CNS and hematopoietic
tissues of EAE mice
To compare the spatio-temporal expression patterns of IL-
36R and its agonists (IL-36α, IL-36β, IL-36γ) in different
MS models, we quantified their mRNAs by quantitative
real-time PCR (qRT-PCR) in nervous and hematopoietic
tissues from mice killed at various time points after EAE in-
duction by either one of the following methods: (1) active
immunization with MOG35-55 peptide in complete Freund’s
adjuvant (CFA) plus PTX (active EAE), (2) adoptive transfer
of splenocytes isolated from EAE mice on day 8 and restim-
ulated in culture for 2 days with MOG35-55 in the presence
of IL-12 and IL-23 (passive EAE), and (3) intraperitoneal in-
jections of PTX to 2D2 mice expressing a transgenic
MOG-specific T cell receptor [55]. Because the latter mice
develop EAE within 2 weeks at an incidence lower than
60 % [24, 55], we killed them at a single time point (day 15)
and separated them into those that had developed EAE ornot (2D2 with or without EAE). Wild-type mice injected
with PBS, PTX, or CFA only were used as controls.
In the spinal cord, IL-36γ and IL-36R mRNAs were
markedly increased in the three EAE models, compared
to control mice and PTX-treated 2D2 mice without EAE
(Fig. 1). An important difference between the active and
passive models is that IL-36γ mRNA peaked at the latest
time point examined (day 12) in the former, whereas it
peaked at day 9 and declined thereafter in the latter. In
the hematopoietic tissues (spleen, blood), IL-36γ mRNA
was increased in active EAE and, to a lesser extent, in
response to PTX and CFA, but not in passive EAE. The
upregulation of IL-36γ was MOG-specific in the spleen
and spinal cord, but mainly attributable to the adjuvants
in the blood. Higher expression of IL-36γ mRNA was
also found in the spleen of 2D2 mice compared to that
of wild-type mice, but there was no difference between
PTX-treated 2D2 mice with or without EAE. IL-36R
mRNA was modestly increased only in the spleen of
mice with active EAE. No significant expression of IL-36α
and IL-36β mRNAs was detected in any of the tissues and
conditions examined (average amounts detected: <220 cop-
ies per μm of total RNA; data not shown). Together, these
results suggest that IL-36γ is the primary IL-36R agonist
that is upregulated during EAE in both CNS and
hematopoietic tissues, where its receptor can also be
expressed.
To identify the cell types expressing IL-36γ and IL-
36R, we first quantified their mRNAs by qRT-PCR in
different leukocytes purified from the spleen or spinal
cord of mice with active EAE (day 12) by flow cytometry
on the basis of established cell-specific markers. In both
tissues, IL-36γ mRNA was detected at high levels only
in Ly6G+ neutrophils, whereas IL-36R was detected in
different cells, especially those of the myeloid lineage
(Fig. 2a). Second, the expression of IL-36γ was con-
firmed at the protein level by Western blotting using
FACS-purified splenic neutrophils (note that it was not
possible to include neutrophils from spinal cords, be-
cause they were less abundant and yielded not enough
proteins). A specific band for IL-36γ was detected at the
predicted molecular weight of ~22 kDa in neutrophils
from IL-36γ+/+ mice, but not from IL-36γ−/− mice
(Fig. 2b). We also attempted to confirm the expression
of IL-36R by flow cytometry using two different anti-
bodies, but none of them provided reliable results, as
the labeling was comparable between IL-36R+/+ and
IL-36R−/− neutrophils and was therefore non-specific
(data not shown). Third, we examined the distribution
of IL-36γ mRNA in spinal cord sections from EAE and
naïve mice by radioisotopic in situ hybridization. Some
of these sections were also immunostained for Ly6G or
the macrophage/microglia marker Iba1. Both tran-
scripts were strongly expressed in EAE mice in areas
Fig. 1 IL-36γ and IL-36R are transcriptionally upregulated in 3 EAE models. Quantification of the mRNAs encoding IL-36γ and IL-36R by qRT-PCR
in different tissues from mice killed at the indicated time points after induction of EAE by either active immunization with MOG peptide, passive
transfer of encephalitogenic T cells, or injection of PTX to 2D2 mice. Control non-transgenic mice were injected with PBS, PTX, or CFA only.
Stars indicate significant differences from the PBS group only (white star) or all the corresponding control groups (black star), as determined
by Wilcoxon tests (P ≤ 0.038). Sample size: 11–13 (PBS), 5–13 (PTX), 4–8 (CFA), 7–8 (active EAE), 5–8 (passive EAE), 6 (2D2 with EAE), or 5 (2D2
without [w/o] EAE)
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mice (Fig. 2c). IL-36γ mRNA was co-localized with
Ly6G+ cells, while IL-36R mRNA was reliably co-
localized only with Iba1+ cells (Fig. 2d), although we
could not exclude its presence in other cell types.
These results led us to conclude that neutrophils can
produce IL-36γ during EAE in both CNS and periph-
eral compartments, potentially to communicate with
microglia and other myeloid cells.
Microglia respond to IL-36γ by expressing inflammatory
genes
To demonstrate that microglia are adequately equipped
to respond to IL-36γ, we first compared the transcrip-
tional profiles of BV2 microglial cells treated or not for
6 h with recombinant IL-36γ using Affymetrix DNA mi-
croarrays. The dose used (100 ng/ml) was chosen be-
cause it was previously reported to be optimal for
stimulating IL-6 secretion from cultured dendritic cells
[38]. Twenty-two genes were found to be upregulated ≥2
times with a hybridization signal ≥100 (Additional file 3:
Table S3 and Fig. 3a). The three most upregulated genes
coded for Csf3, IL-1β, and Cxcl2, which are well known
to be involved in neutrophil biology [56]. Quantitative
PCR analysis confirmed that these 3 genes were stronglyupregulated in BV2 cells by IL-36γ (Fig. 3b). To validate
these results, we repeated the experiment with primary
microglia collected from IL-36R+/+ and IL-36R−/− mice. As
expected, upregulation of Csf3, IL-1β, and Cxcl2 were ob-
served in IL-36R+/+ microglia following IL-36γ exposure,
but not in IL-36R−/− microglia (Fig. 3c). The latter cells
were not devoid of the ability to express these genes
because they expressed them at the same levels as IL-
36R+/+ microglia when stimulated with lipopolysac-
charide (10 ng/ml; data not shown). Altogether, these
results indicate that microglia have the potential to re-
spond to IL-36γ, at least ex vivo.
The IL-36γ–IL-36R axis does not influence the course of
active EAE
As IL-36γ and IL-36R are strongly and chronically
expressed in active EAE (Figs. 1 and 2) and as the resi-
dent macrophages of the CNS can potentially respond
to IL-36γ (Fig. 3), we hypothesized that the loss of
these proteins would have an impact on the clinical
course of active EAE. To address this possibility, we
induced the disease in mice deficient or not in either
IL-36γ or IL-36R and then scored their symptoms
daily for 21 days. As shown in Fig. 4, the incidence,
onset, and severity of EAE were similar between the
Fig. 2 IL-36γ is selectively expressed by neutrophils, while IL-36R is expressed by different leukocytes such as monocytic cells. a Quantification of
IL-36γ or IL36R mRNA by qRT-PCR in different cells purified from the spinal cord or spleen of EAE mice by FACS using the following gating strategies:
neutrophils, Ly6G+CD11b+CD45+CD3−CD19−; microglia, CD11b+CD45lowLy6G−CD3−CD19−; monocyte-derived cells (MDC; comprising macrophages and
CD11c+ dendritic cells), CD11b+CD45+CD11c+/−Ly6G−CD3−CD19−; other intraspinal leukocytes, CD45+CD3+/−CD19+/−CD11b−Ly6G−CD11c−; B cells, CD19
+CD45+CD11b−Ly6G−CD3−; splenic macrophages, CD11b+CD45+CD11c−Ly6G−CD3−CD19−; other splenic leukocytes, CD45+CD3+/−CD11b+/−CD11c+/−Ly6G
−CD19−. Sample size: spinal cord, one pooled sample of sorted cells from four mice; spleen, five non-pooled samples from individual mice. bWestern
blotting showing the full-length form of IL-36γ (~22 kDa) in splenic neutrophils from a wild-type EAE mouse (IL-36γ+/+), but not from an IL-36γ-deficient
EAE mouse (IL-36γ−/−). Data are representative of at least four mice per group. The recombinant (truncated) form of IL-36γ was used as a control (right lane).
β-actin (lower panels) was used to control for protein loading. Asterisks indicate non-specific bands. c Autoradiograms showing in situ hybridization signals
(arrows) for IL-36γ or IL-36R mRNA in the spinal cord of mice killed on day 12 after active EAE induction, but not in naïve mice. Note the submeningeal
distribution of the signals (representative of at least five mice). Scale bar = 500 μm. d Double labeling for IL-36γ or IL-36R mRNA (black grains, in situ
hybridization) and cell type-specific markers (red brown, immunohistochemistry) in CNS sections from EAE mice. Arrows show examples of double-labeled
cells. Scale bar = 20 μm
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whether the genetic deletions had influenced the na-
ture of the immune cells infiltrating the CNS, we
killed all of the mice on day 21 and prepared single-
cell suspensions from their spinal cords for flow cy-
tometric analysis. Consistently with the behavioral
observations, no intergenotype difference was observed
in the number of microglia, macrophages, dendritic cells,
neutrophils as well as of T and B cells (Fig. 5). Therefore,these results demonstrate that the IL-36γ-IL-36R axis does
not play a significant role in the autoimmune response in-
volved in active EAE.
Discussion
As observed in other immunological diseases such as
psoriasis [29, 32, 34, 57, 58], the present study shows
that IL-36γ and IL-36R are upregulated in the three
models of EAE. It also shows that IL-36γ derives from
Fig. 3 IL-36γ stimulates the expression of inflammatory genes in microglial cultures. a Genes that were upregulated ≥2.5 times in BV2 microglia
treated for 6 h with recombinant IL-36γ (100 ng/ml) compared to PBS, as determined using Affymetrix DNA microarrays (Student’s t test, P < 0.04).
b, c Quantitative PCR analysis confirming that Csf3, IL-1β, and Cxcl2 mRNAs were upregulated by IL-36γ in BV2 cells (b) and primary microglia
from IL-36R+/+ mice (c) (Wilcoxon test, P < 0.005). Note in c the absence of upregulation in primary microglia from IL-36R−/− mice, confirming the
specificity of the results
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neutrophil-stimulating cytokines, which is consistent
with previous studies showing that IL-36γ induces both
the production of such cytokines in other myeloid cells
residing outside the CNS [31, 38, 40–42] and the re-
cruitment of neutrophils [42]. Despite these observa-
tions, we demonstrate that neither IL-36γ nor IL-36R
plays a significant role in EAE, similarly to what wasFig. 4 Neither IL-36γ nor IL-36R is required for EAE development. a Kaplan
or lacking (white squares) IL-36γ (upper graph) or IL-36R (bottom graph) afte
significant intergenotype difference was detected (Wilcoxon tests, P ≥ 0.41)
b EAE severity in mice expressing (black squares) or lacking (white squares)
mice that had developed clinical signs of EAE at the end of the study (i.e.,
tests, P≥ 0.12). Sample size: 17 (IL-36γ+/+), 17 (IL-36γ−/−), 5 (IL-36R+/+), or 5 (IL-36
IL-36γ or IL-36R. No significant intergenotype difference was detected in any of
20 (IL-36γ−/−), 6 (IL-36R+/+), or 6 (IL-36R−/−)reported in murine models of arthritis [59, 60] and
mycobacterial infection [61].
The main question that arises is why IL-36γ is
expressed, but does not play a role in certain conditions.
One hypothesis is that IL-36γ, like other members of the
IL-1 family, requires a second signal to be processed, ac-
tivated, and secreted. This signal would be present in
psoriasis, but not in EAE and arthritis models. In-Meier curves showing EAE incidence in mice expressing (black squares)
r immunization with MOG. The graphs include all the mice tested. No
. Sample size: 20 (IL-36γ+/+), 20 (IL-36γ−/−), 6 (IL-36R+/+), or 6 (IL-36R−/−).
IL-36γ (upper graph) or IL-36R (bottom graph). The graphs include only
21 days). No significant intergenotype difference was detected (Wilcoxon
R−/−). c Additional statistics for EAE in mice expressing (+/+) or not (−/−)
these parameters (Wilcoxon tests, P≥ 0.34). Sample size: 20 (IL-36γ+/+),
Fig. 5 No difference in leukocyte recruitment in the spinal cord of EAE mice expressing or not IL-36γ or IL-36R. a Gating strategy used for flow cytometric
analysis. Dead cells and doublets were excluded. The data shown are from a representative wild-type EAE mouse. b, c Counts of immune cells in the spinal
cord of IL-36γ−/−, IL-36R−/−, or wild-type mice killed 21 days after immunization with MOG peptide. The counts were normalized to CD45− cells used as an
internal control. When the cells were collected, the animals had clinical scores ranging from 0.5 to 3. No significant difference was found between the
genotypes (Wilcoxon tests, P≥ 0.07). Sample size: 6 (b) or 9 (c) mice per group
Bozoyan et al. Journal of Neuroinflammation  (2015) 12:173 Page 8 of 10support of this, it has been shown that IL-36γ requires
N-terminal truncation to be fully active [27]. However, it
is unknown whether this truncation occurs in vivo and
what would be the protease involved. Our work shows,
for the first time to our knowledge, that the full-length
IL-36γ protein (193 amino acids, 22 kDa) is detectable
in vivo (i.e., in neutrophils from EAE mice). As the
truncated form is not detectable in the same condi-
tions, it is likely that IL-36γ remains stored under a
pro-form in the cytoplasm of neutrophils during EAE.
A second (non-exclusive) hypothesis is that neutrophils re-
lease IL-36γ during a cell death process such as NETosis,
which occurs in psoriasis [62], but not likely in EAE. This
possibility that IL-36γ acts as an alarmin (i.e., an endogen-
ous molecule that signals tissue and cell damage) is so far
only supported by the observation that the TLR3 agonist
polyinosinic-polycytidylic acid concomitantly induces cell
death and IL-36γ release in keratinocyte cultures [35]. Fi-
nally, a third hypothesis is that the CNS, an immunoprivi-
leged site, has a higher activation threshold to IL-36γ due
to a combination of mechanisms (e.g., via the secretion of
IL-36 antagonists and the generation of intracellular signal-
ing inhibitors such as SIGIRR [63]).A positive aspect of this study is that we have identified
microglia as a potential target of IL-36γ. This suggests that
IL-36γ could contribute to neuroinflammation, perhaps by
promoting neutrophil recruitment, in certain conditions
that remain to be determined. Another positive aspect is
that we have identified neutrophils as a major and exclusive
source of IL-36γ in nervous and hematopoietic tissues (i.e.,
brain, spinal cord, spleen, blood). According to previous
studies, keratinocytes and other epithelial cells can also
produce IL-36γ in culture [30–34, 64], but, to our
knowledge, this remains to be confirmed in vivo.
Therefore, it will be important in the future to deter-
mine whether neutrophils are a predominant source of
IL-36γ in epithelial inflammatory diseases (e.g., psoria-
sis, asthma) as they are in EAE.
In conclusion, this study demonstrates that components
of the IL-36 signaling pathway are strongly expressed in
EAE, but that they do not contribute to this pathology. Fur-
thermore, by revealing that IL-36γ is a neutrophil-specific
marker in different tissues and that microglia have the po-
tential to response to this cytokine, this study opens up
new research avenues for elucidating the biological function
of IL-36γ and its clinical significance.
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